Chronic lymphocytic leukaemia

Lancet
Michael HallekBarbara Eichhorst

Abstract

Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management.

Citations

Dec 18, 2018·Journal of the Peripheral Nervous System : JPNS·Chiara BrianiFrancesco Piazza
Apr 25, 2019·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Henry Y L HuiWendy N Erber
May 30, 2019·The New England Journal of Medicine·Nitin JainWilliam Wierda
Jun 13, 2019·Hematological Oncology·Michael Hallek, Moritz Fürstenau
Sep 25, 2019·Leukemia & Lymphoma·Haibin ZhangXiaozhong Wang
Jan 17, 2020·HemaSphere·Moritz FürstenauMichael Hallek
Apr 17, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Noelle V FreyDavid L Porter
May 28, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paolo GhiaWojciech Jurczak
Jul 29, 2020·Blood Research·Jieun Uhm
Jan 18, 2020·Haematologica·Enrique PodazaMirta Giordano
May 23, 2018·Cancers·Sarah LuuRobert K Andrews
Feb 13, 2020·Der Internist·Othman Al-SawafMichael Hallek
Mar 14, 2020·Cancers·Riccardo MoiaGianluca Gaidano
Feb 29, 2020·Current Hematologic Malignancy Reports·Jason C Lee, Nicole Lamanna
Apr 11, 2020·Frontiers in Cell and Developmental Biology·Anna OnnisCosima T Baldari
Jun 6, 2019·The New England Journal of Medicine·Kirsten FischerMichael Hallek
Jun 25, 2020·Experimental Hematology & Oncology·Ying DongQi Wang
May 28, 2020·Frontiers in Immunology·Margaux LejeuneJo Caers
Feb 23, 2019·Frontiers in Immunology·Javier Redondo-MuñozJoaquin Teixidó
Dec 5, 2019·International Journal of Hematology·Yoshikane Kikushige
Apr 21, 2020·HemaSphere·Moritz FürstenauSibylle C Mellinghoff
Oct 6, 2020·Expert Opinion on Therapeutic Targets·Riccardo MoiaGianluca Gaidano
Nov 3, 2020·The Journal of Experimental Medicine·Xiaofei YeQiang Pan-Hammarström
Nov 6, 2020·Journal of Clinical and Experimental Hematopathology : JCEH·Takayoshi UchiyamaSadao Aoki
Nov 6, 2020·Journal of Clinical and Experimental Hematopathology : JCEH·Yoshikane Kikushige

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.